{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:01:19Z","timestamp":1761919279876,"version":"3.37.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T00:00:00Z","timestamp":1262044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T00:00:00Z","timestamp":1262044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/tpj.2009.57","type":"journal-article","created":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T10:55:52Z","timestamp":1262084152000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform"],"prefix":"10.1038","volume":"10","author":[{"given":"J F","family":"Deeken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Cormier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D K","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T M","family":"Sissung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D J","family":"Liewehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W L","family":"Dahut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W D","family":"Figg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,29]]},"reference":[{"key":"BFtpj200957_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CAD.0b013e3280109411","volume":"18","author":"J Deeken","year":"2007","unstructured":"Deeken J, Figg W, Bates SE, Sparreboom A . Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007; 18: 111\u2013126.","journal-title":"Anticancer Drugs"},{"key":"BFtpj200957_CR2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(25)07385-4","volume":"24","author":"A Sparreboom","year":"1996","unstructured":"Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 1996; 24: 655\u2013668.","journal-title":"Drug Metab Dispos"},{"key":"BFtpj200957_CR3","first-page":"1296","volume":"56","author":"F Marre","year":"1996","unstructured":"Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R . Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56: 1296\u20131302.","journal-title":"Cancer Res"},{"key":"BFtpj200957_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00008571-199810000-00004","volume":"8","author":"M Shou","year":"1998","unstructured":"Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV . Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8: 391\u2013401.","journal-title":"Pharmacogenetics"},{"key":"BFtpj200957_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","volume":"36","author":"SJ Clarke","year":"1999","unstructured":"Clarke SJ, Rivory LP . Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99\u2013114.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj200957_CR6","first-page":"1255","volume":"6","author":"J Hirth","year":"2000","unstructured":"Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH . The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255\u20131268.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200957_CR7","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1200\/JCO.2002.01.025","volume":"20","author":"BC Goh","year":"2002","unstructured":"Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683\u20133690.","journal-title":"J Clin Oncol"},{"key":"BFtpj200957_CR8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.clpt.2004.01.001","volume":"75","author":"FK Engels","year":"2004","unstructured":"Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75: 448\u2013454.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj200957_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00280-004-0823-0","volume":"54","author":"F Puisset","year":"2004","unstructured":"Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Az\u00e9ma J et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004; 54: 265\u2013272.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj200957_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4161\/cbt.5.7.2839","volume":"5","author":"FK Engels","year":"2006","unstructured":"Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J . Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006; 5: 833\u2013839.","journal-title":"Cancer Biol Ther"},{"key":"BFtpj200957_CR11","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1158\/1078-0432.CCR-05-2649","volume":"12","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 5786\u20135793.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200957_CR12","first-page":"333","volume":"20","author":"JS Park","year":"2002","unstructured":"Park JS, Yamamoto W, Sekikawa T, Matsukawa M, Okamoto R, Sasaki M et al. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 2002; 20: 333\u2013338.","journal-title":"Int J Oncol"},{"key":"BFtpj200957_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1200\/JCO.2005.09.078","volume":"23","author":"K Iwao-Koizumi","year":"2005","unstructured":"Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422\u2013431.","journal-title":"J Clin Oncol"},{"key":"BFtpj200957_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","volume":"79","author":"A Tran","year":"2006","unstructured":"Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570\u2013580.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj200957_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4161\/cbt.5.7.3025","volume":"5","author":"WD Figg","year":"2006","unstructured":"Figg WD, Chau CH . Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics. Cancer Biol Ther 2006; 5: 840\u2013851.","journal-title":"Cancer Biol Ther"},{"key":"BFtpj200957_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1476-5381.1965.tb02053.x","volume":"25","author":"H Schumacher","year":"1965","unstructured":"Schumacher H, Smith RL, Williams RT . The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol Chemother 1965; 25: 324\u2013337.","journal-title":"Br J Pharmacol Chemother"},{"key":"BFtpj200957_CR17","doi-asserted-by":"publisher","first-page":"149158","DOI":"10.1002\/tcm.1770050304","volume":"5","author":"AG Braun","year":"1985","unstructured":"Braun AG, Weinreb SL . Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. Teratog Carcinog Mutagen 1985; 5: 149158.","journal-title":"Teratog Carcinog Mutagen"},{"key":"BFtpj200957_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/00007691-200202000-00017","volume":"24","author":"DK Price","year":"2002","unstructured":"Price DK, Ando Y, Kruger EA, Weiss M, Figg WD . 5\u2032-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit 2002; 24: 104\u2013110.","journal-title":"Ther Drug Monit"},{"key":"BFtpj200957_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2174\/138920006778017777","volume":"7","author":"ER Lepper","year":"2006","unstructured":"Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD . Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 2006; 7: 677\u2013685.","journal-title":"Curr Drug Metab"},{"key":"BFtpj200957_CR20","first-page":"1964","volume":"8","author":"Y Ando","year":"2002","unstructured":"Ando Y, Fuse E, Figg WD . Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002; 8: 1964\u20131973.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200957_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/dmd.31.4.469","volume":"31","author":"M Miyata","year":"2003","unstructured":"Miyata M, Tamura E, Motoki K, Nagata K, Yamazoe Y . Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation. Drug Metab Dispos 2003; 31: 469\u2013475.","journal-title":"Drug Metab Dispos"},{"key":"BFtpj200957_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1124\/jpet.104.067793","volume":"310","author":"J Lu","year":"2004","unstructured":"Lu J, Helsby N, Palmer BD, Tingle M, Baguley BC, Kestell P et al. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J Pharmacol Exp Ther 2004; 310: 571\u2013577.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj200957_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4161\/cbt.318","volume":"1","author":"Y Ando","year":"2002","unstructured":"Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD . Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 2002; 1: 669\u2013673.","journal-title":"Cancer Biol Ther"},{"key":"BFtpj200957_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/14622416.8.3.293","volume":"8","author":"C Dumaual","year":"2007","unstructured":"Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix targeted genotyping system. Pharmacogenomics 2007; 8: 293\u2013305.","journal-title":"Pharmacogenomics"},{"key":"BFtpj200957_CR25","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","volume":"22","author":"WL Dahut","year":"2004","unstructured":"Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532\u20132539.","journal-title":"J Clin Oncol"},{"key":"BFtpj200957_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"16","author":"R Bruno","year":"1998","unstructured":"Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT et al. Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187\u2013196.","journal-title":"J Clin Oncol"},{"key":"BFtpj200957_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1010687017717","volume":"19","author":"R Bruno","year":"2001","unstructured":"Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR . Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163\u2013169.","journal-title":"Invest New Drugs"},{"key":"BFtpj200957_CR28","first-page":"1077","volume":"9","author":"R Bruno","year":"2003","unstructured":"Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003; 9: 1077\u20131082.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200957_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.urology.2007.06.1097","volume":"70","author":"A Hamada","year":"2007","unstructured":"Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D et al. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 2007; 70: 217\u2013220.","journal-title":"Urology"},{"key":"BFtpj200957_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","volume":"80","author":"ER Gardner","year":"2006","unstructured":"Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80: 192\u2013201.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj200957_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/1535-7163.MCT-07-0557","volume":"7","author":"TM Sissung","year":"2008","unstructured":"Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008; 7: 19\u201326.","journal-title":"Mol Cancer Ther"},{"key":"BFtpj200957_CR32","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1158\/1078-0432.CCR-05-0520","volume":"11","author":"ER Lepper","year":"2005","unstructured":"Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005; 11: 7398\u20137404.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200957_CR33","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1158\/1078-0432.CCR-07-4230","volume":"14","author":"TM Sissung","year":"2008","unstructured":"Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008; 14: 4543\u20134549.","journal-title":"Clin Cancer Res"},{"key":"BFtpj200957_CR34","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4161\/cbt.322","volume":"1","author":"Y Honjo","year":"2002","unstructured":"Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR\/BCRP\/ABCP1). Cancer Biol Ther 2002; 1: 696\u2013702.","journal-title":"Cancer Biol Ther"},{"key":"BFtpj200957_CR35","first-page":"427","volume":"78","author":"CR Mehta","year":"1983","unstructured":"Mehta CR, Patel NR . A network algorithm for performing Fisher's exact test in r \u00d7 c contingency tables. J Am Stat Assoc 1983; 78: 427\u2013434.","journal-title":"J Am Stat Assoc"},{"key":"BFtpj200957_CR36","doi-asserted-by":"publisher","first-page":"19313","DOI":"10.1074\/jbc.M702329200","volume":"282","author":"DK Kr\u00e4mer","year":"2007","unstructured":"Kr\u00e4mer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A . Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007; 282: 19313\u201319320.","journal-title":"J Biol Chem"},{"key":"BFtpj200957_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/01.ATV.0000064383.88696.24","volume":"23","author":"J Skogsberg","year":"2003","unstructured":"Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E . Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003; 23: 637\u2013643.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFtpj200957_CR38","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.2337\/diabetes.54.12.3587","volume":"54","author":"M V\u00e4nttinen","year":"2005","unstructured":"V\u00e4nttinen M, Nuutila P, Kuulasmaa T, Pihlajam\u00e4ki J, H\u00e4llsten K, Virtanen KA et al. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. Diabetes 2005; 54: 3587\u20133591.","journal-title":"Diabetes"},{"key":"BFtpj200957_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/archpsyc.65.7.785","volume":"65","author":"PP Zandi","year":"2008","unstructured":"Zandi PP, Belmonte PL, Willour VL, Goes FS, Badner JA, Simpson SG et al. Association study of Wnt signaling pathway genes in bipolar disorder. Arch Gen Psychiatry 2008; 65: 785\u2013793.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj200957_CR40","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1210\/jc.2009-0392","volume":"94","author":"LR Burch","year":"2009","unstructured":"Burch LR, Zhou K, Donnelly LA, Doney AS, Brady J, Goddard C et al. A single nucleotide polymorphism on exon-4 of the gene encoding PPAR{delta} is associated with reduced height in adults and children. J Clin Endocrinol Metab 2009; 94: 2587\u20132593.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj200957_CR41","doi-asserted-by":"publisher","first-page":"12890","DOI":"10.1073\/pnas.0705505104","volume":"104","author":"A Abdollahi","year":"2007","unstructured":"Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 2007; 104: 12890\u201312895.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj200957_CR42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/gcc.20569","volume":"47","author":"SH Nordgard","year":"2008","unstructured":"Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syv\u00e4nen AC, Naume B et al. Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer 2008; 47: 680\u2013696.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFtpj200957_CR43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.69.4.565","volume":"69","author":"X Li","year":"2001","unstructured":"Li X, Tu L, Murphy PG, Kadono T, Steeber DA, Tedder TF . CHST1 and CHST2 sulfotransferase expression by vascular endothelial cells regulates shear-resistant leukocyte rolling via L-selectin. J Leukoc Biol 2001; 69: 565\u2013574.","journal-title":"J Leukoc Biol"},{"key":"BFtpj200957_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2133\/dmpk.19.422","volume":"19","author":"M Nishimura","year":"2004","unstructured":"Nishimura M, Imai T, Morioka Y, Kuribayashi S, Kamataki T, Naito S . Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. Drug Metab Pharmacokinet 2004; 19: 422\u2013429.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFtpj200957_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10038-002-8650-9","volume":"47","author":"A Iida","year":"2002","unstructured":"Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K et al. Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes. J Hum Genet 2002; 47: 14\u201319.","journal-title":"J Hum Genet"},{"key":"BFtpj200957_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1006\/bbrc.2000.2744","volume":"272","author":"L Xiangrong","year":"2000","unstructured":"Xiangrong L, J\u00f6hnk C, Hartmann D, Schestag F, Kr\u00f6mer W, Gieselmann V . Enzymatic properties, tissue-specific expression, and lysosomal location of two highly homologous rat SULT1C2 sulfotransferases. Biochem Biophys Res Commun 2000; 272: 242\u2013250.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFtpj200957_CR47","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1248\/bpb.24.1258","volume":"24","author":"HO Tamura","year":"2001","unstructured":"Tamura HO, Taniguchi K, Hayashi E, Hiyoshi Y, Nagai F . Expression profiling of sulfotransferases in human cell lines derived from extra-hepatic tissues. Biol Pharm Bull 2001; 24: 1258\u20131262.","journal-title":"Biol Pharm Bull"},{"key":"BFtpj200957_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.tpj.6500404","volume":"7","author":"MA Hildebrandt","year":"2007","unstructured":"Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC et al. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J 2007; 7: 133\u2013143.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj200957_CR49","first-page":"1079","volume":"26","author":"S Aust","year":"2005","unstructured":"Aust S, Obrist P, Klimpfinger M, Tucek G, J\u00e4ger W, Thalhammer T . Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. Int J Oncol 2005; 26: 1079\u20131085.","journal-title":"Int J Oncol"},{"key":"BFtpj200957_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mce.2005.06.003","volume":"240","author":"EL Stanley","year":"2005","unstructured":"Stanley EL, Hume R, Coughtrie MW . Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification. Mol Cell Endocrinol 2005; 240: 32\u201342.","journal-title":"Mol Cell Endocrinol"},{"key":"BFtpj200957_CR51","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0092-8674(00)81203-9","volume":"93","author":"G Casari","year":"1998","unstructured":"Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, Fernandez P et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 1998; 93: 973\u2013983.","journal-title":"Cell"},{"key":"BFtpj200957_CR52","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1074\/jbc.M610314200","volume":"282","author":"A Goytain","year":"2007","unstructured":"Goytain A, Hines RM, El-Husseini A, Quamme GA . NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg2+ transporter. J Biol Chem 2007; 282: 8060\u20138068.","journal-title":"J Biol Chem"},{"key":"BFtpj200957_CR53","first-page":"58","volume":"56","author":"I Royer","year":"1996","unstructured":"Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T . Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58\u201365.","journal-title":"Cancer Res"},{"key":"BFtpj200957_CR54","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P","volume":"14","author":"SK Teo","year":"2000","unstructured":"Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD . Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol 2000; 14: 140\u2013147.","journal-title":"J Biochem Mol Toxicol"},{"key":"BFtpj200957_CR55","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/ije\/dyh251","volume":"33","author":"G McKeown-Eyssen","year":"2004","unstructured":"McKeown-Eyssen G, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004; 33: 971\u2013978.","journal-title":"Int J Epidemiol"},{"key":"BFtpj200957_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00008571-199704000-00006","volume":"7","author":"N Sabbagh","year":"1997","unstructured":"Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F . NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997; 7: 131\u2013135.","journal-title":"Pharmacogenetics"},{"key":"BFtpj200957_CR57","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","volume":"155","author":"DP Parkin","year":"1997","unstructured":"Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717\u20131722.","journal-title":"Am J Respir Crit Care Med"},{"key":"BFtpj200957_CR58","first-page":"6172","volume":"62","author":"MG Belinsky","year":"2002","unstructured":"Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD . Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 2002; 62: 6172\u20136177.","journal-title":"Cancer Res"},{"key":"BFtpj200957_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2004.09.007","volume":"53","author":"R Safaei","year":"2005","unstructured":"Safaei R, Howell SB . Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005; 53: 13\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFtpj200957_CR60","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1152\/physrev.00027.2002","volume":"83","author":"M Trauner","year":"2003","unstructured":"Trauner M, Boyer JL . Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633\u2013671.","journal-title":"Physiol Rev"},{"key":"BFtpj200957_CR61","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1200\/JCO.2007.12.7803","volume":"25","author":"ML Maitland","year":"2007","unstructured":"Maitland ML, Ratain MJ, Cox NJ . Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol 2007; 25: 4513\u20134515.","journal-title":"J Clin Oncol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj200957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj200957","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj200957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T11:57:39Z","timestamp":1739707059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj200957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,29]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["BFtpj200957"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2009.57","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"type":"print","value":"1470-269X"},{"type":"electronic","value":"1473-1150"}],"subject":[],"published":{"date-parts":[[2009,12,29]]},"assertion":[{"value":"24 November 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TC, KT and XM are employees of Affymetrix, the manufacturer of the DMET platform. JFD serves as a consultant to Sanofi-Aventis, the manufacturer of docetaxel.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}